Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Botaluma is a branded botulinum toxin type A injectable neurotoxin product used for aesthetic and/or therapeutic indications, analogous to other botulinum toxin type A formulations such as Botox, although detailed public information specific to this brand is limited. Like other botulinum toxin type A preparations, it is expected to act by cleaving the synaptic protein SNAP-25 in cholinergic nerve terminals, thereby blocking acetylcholine release at the neuromuscular junction and autonomic synapses, producing a temporary chemodenervation of targeted muscles or glands and resulting in reduced muscle contraction or secretory activity. The product is formulated as a biologic protein toxin derived from Clostridium botulinum and administered in very low doses by local injection to achieve focal effects with minimal systemic exposure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Botaluma.